ArticleDrug and alcohol dependence2025
Reliability and clinical utility of heroin craving questionnaire factors in treatment-enrolled individuals with opioid use disorder.
Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Psychometric properties of opioid craving assessments are underexamined, limiting their potential utility for treatment studies of opioid use disorder (OUD). To address this gap, the current study aimed to evaluate the predictive utility of the Heroin Craving Questionnaire (HCQ) for future substance use outcomes. Treatment-enrolled participants with OUD (n = 128) completed the Heroin Craving Questionnaire (HCQ) at baseline and were followed up to assess future return to use versus abstinence. Individuals who maintained abstinence at each of three follow-up visits also completed the HCQ again. Exploratory factor analysis (EFA) was performed on baseline HCQ items, and extracted factors were evaluated for: (1) internal consistency reliability (Cronbach's alpha); (2) associations with demographic and clinical variables; (3) follow-up group differences; (4) test-retest reliability (intraclass coefficients: ICCs); and (5) change across visits. EFA results produced a three-factor structure, retaining 30 of 45 HCQ items and accounting for 54.60 % of the variance: (1) Lack of Self-Control (10 items, alpha=.93); (2) Positive Expectancies (11 items, alpha=.91); and (3) Urgency (9 items, alpha=.89). Results indicated that: (1) elevated scores on all three factors were associated with comorbid amphetamine use disorder; (2) higher Lack of Self-Control and Positive Expectancies scores related to fewer days since last heroin use; (3) greater Lack of Self-Control and Urgency scores were associated with higher anxiety severity; and (4) ICCs showed moderate to good test-retest reliability between baseline and follow-up visits. However, factor scores at baseline could not differentiate future relapsers versus abstainers. More research is warranted to replicate these factors in additional OUD samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.